These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12397912)

  • 41. Abortion pill gets FDA approval.
    SoRelle R
    Circulation; 2000 Oct; 102(15):E9030-1. PubMed ID: 11183868
    [No Abstract]   [Full Text] [Related]  

  • 42. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M
    Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
    [No Abstract]   [Full Text] [Related]  

  • 45. Linezolid: MAOI activity and potential drug interactions.
    Hammerness P; Parada H; Abrams A
    Psychosomatics; 2002; 43(3):248-9. PubMed ID: 12075044
    [No Abstract]   [Full Text] [Related]  

  • 46. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.
    Morales N; Vermette H
    Psychosomatics; 2005; 46(3):274-5. PubMed ID: 15883150
    [No Abstract]   [Full Text] [Related]  

  • 47. ADHD, methylphenidate and driving: does some legislation endanger public health?
    Verster JC; Cox DJ
    J Psychopharmacol; 2008 May; 22(3):227-9. PubMed ID: 18541623
    [No Abstract]   [Full Text] [Related]  

  • 48. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results.
    Wigal SB; Wilens TE; Wolraich M; Lerner M
    Pediatrics; 2007 Jul; 120(1):e120-8. PubMed ID: 17548486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Basics of the drug therapy for attention deficit hyperactivity disorders in adolescents].
    Airaksinen E; Airaksinen MM
    Duodecim; 2003; 119(16):1553-62. PubMed ID: 14535028
    [No Abstract]   [Full Text] [Related]  

  • 51. Attention deficit/hyperactivity disorder: working the system for better diagnosis and treatment.
    Stevens S
    J Pediatr Nurs; 2005 Feb; 20(1):47-51. PubMed ID: 15834359
    [No Abstract]   [Full Text] [Related]  

  • 52. The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders.
    Cho SC; Hwang JW; Kim BN; Lee HY; Kim HW; Lee JS; Shin MS; Lee DS
    J Psychiatr Res; 2007 Sep; 41(6):459-65. PubMed ID: 16839567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.
    Biederman J
    J Clin Psychiatry; 2006; 67 Suppl 8():4-6. PubMed ID: 16961423
    [No Abstract]   [Full Text] [Related]  

  • 54. Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants.
    Aga VM; Barklage NE; Jefferson JW
    J Clin Psychiatry; 2003 May; 64(5):609-11. PubMed ID: 12755668
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?
    Mott TF; Leach L; Johnson L
    J Fam Pract; 2004 Aug; 53(8):659-61. PubMed ID: 15298843
    [No Abstract]   [Full Text] [Related]  

  • 57. Delta plots in the study of individual differences: new tools reveal response inhibition deficits in AD/Hd that are eliminated by methylphenidate treatment.
    Ridderinkhof KR; Scheres A; Oosterlaan J; Sergeant JA
    J Abnorm Psychol; 2005 May; 114(2):197-215. PubMed ID: 15869351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inappropriate prescription of methylphenidate.
    Cooper N
    N Z Med J; 2003 Oct; 116(1183):U636. PubMed ID: 14581947
    [No Abstract]   [Full Text] [Related]  

  • 59. Methylphenidate and the cytochrome P450 system.
    Baird R
    Can J Psychiatry; 2003 Jul; 48(6):425-6; author reply 426. PubMed ID: 12894619
    [No Abstract]   [Full Text] [Related]  

  • 60. [After the researchers have left the field].
    Boer F
    Tijdschr Psychiatr; 2007; 49(8):525-7. PubMed ID: 17824135
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.